We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study.
- Authors
Eskiyurt, Nurten; İrdesel, Jale; Sepici, Vesile; Uğurlu, Hatice; Kirazlı, Yeşim; Ardıç, Füsun; Btn, Blent; Akyz, Glseren; Cerrahoğlu, Lale; Şendur, mer Faruk; Yalın, Peyman; ncel, Sema; Sarıdoğan, Merih; Sarpel, Tunay; Tosun, Mehmet; Kutsal, Yeşim Gke; Şenel, Kazım; Grsoy, Savaş; Cantrk, Ferhan; Demir, Hseyin
- Abstract
Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4 points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (≥80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment.
- Subjects
TURKEY; DIPHOSPHONATES; CLINICAL trials; STATISTICAL correlation; LONGITUDINAL method; MEDICAL cooperation; OSTEOPOROSIS; QUALITY of life; QUESTIONNAIRES; RESEARCH; RESEARCH funding; STATISTICS; U-statistics; DATA analysis; POSTMENOPAUSE; PATIENTS' attitudes; DESCRIPTIVE statistics
- Publication
Turkish Journal of Osteoporosis / Turk Osteoporoz Dergisi, 2012, Vol 18, Issue 1, p1
- ISSN
2146-3816
- Publication type
Article
- DOI
10.4274/tod.29491